In today’s world, losing weight isn’t just about fitting into your old jeans—it’s about reclaiming your energy, confidence, ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Why is an increase of nearly 48% in India’s coastline relevant to the UPSC exam? What is the significance of topics such as ...

A new study has shown that the physical structure of food affects the hormones released as part of digestion. This means that ...

A new study from Imperial has shown that the physical structure of food influences the hormones released as part of digestion ...

A new study from Imperial has shown that the physical structure of food influences the hormones released as part of digestion.These hormones ...

Oprah Winfrey and Elon Musk endorsed it. And though Indian celebrities haven’t yet admitted to their use, the mystery ...

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.

Martin Vollmer, biopharma program manager at Agilent Technologies, spoke to LCGC International about the evolving importance of glucagon-like peptide-1 (GLP-1) therapeutics and the challenges they ...

Dietary protein intake is a potent stimulus inducing the secretion of these hormones, including glucagon-like peptide-1 (GLP-1). GLP-1 is an incretin responsible for controlling food intake and ...

Projections for the near future indicate that the glucagon-like peptide GLP-1 agonists weight loss drugs market size will continue to surge, reaching $28.91 billion in 2029 at a CAGR of 16.6%.